GM2-KLH vaccine

Phase 3Vaccine

EEuropean Organisation for Research and Treatment of Cancer - EORTC

GM2-KLH vaccine is one of 57 biologic programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

GM2-KLH vaccine

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Phase 3

1 3

Lexiscan

Astellas

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Motexafin Gadolinium

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Melanoma1 trial

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00005052

Breast Cancer1 trial

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003357·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GM2-KLH vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GM2-KLH vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GM2-KLH vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

GM2-KLH vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Melanoma1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News